ArticleBMC public health2019
A ten-year China-US laboratory collaboration: improving response to influenza threats in China and the world, 2004-2014.
Article in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Assessing the Origin of the COVID19 Pandemic Is Still Important.FASEB bioAdvances · 2026Article
- Effects of Residential Greenness on Influenza Virus Infection in 1,012,430 People: A Nationwide Individual-Level Study in China.Environment & health (Washington, D.C.) · 2025Article
- Rapid aging of influenza epidemics in China from 2005/06 to 2016/17: A population-based study.Infectious Disease Modelling · 2025Article
- Effect of Rapid Urbanization in Mainland China on the Seasonal Influenza Epidemic: Spatiotemporal Analysis of Surveillance Data From 2010 to 2017.JMIR public health and surveillance · 2023Article
- The Epidemiology of Influenza and the Associated Vaccines Development in China: A Review.Vaccines · 2022Review
- Comprehensive Vaccine-Preventable Disease Surveillance in the Western Pacific Region: A Literature Review on Integration of Surveillance Functions, 2000-2021.Global health, science and practice · 2022Review
- Unpacking multi-level governance of antimicrobial resistance policies: the case of Guangdong, China.Health policy and planning · 2022Article
- Article
- Perceptions and knowledge regarding the COVID-19 pandemic between U.S. and China: a mixed methods study.Globalization and health · 2022Article
- Estimated Incidence of Seasonal Influenza in China From 2010 to 2020 Using a Multiplier Model.JAMA network open · 2022Article
- US-China health exchange and collaboration following COVID-19.Lancet (London, England) · 2021Article
- Influenza-associated cardiovascular mortality in older adults in Beijing, China: a population-based time-series study.BMJ open · 2020Article
- Strengthening China's Public Health Response System: From SARS to COVID-19.American journal of public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
Abstract
The emergence of severe acute respiratory syndrome (SARS) underscored the importance of influenza detection and response in China. From 2004, the Chinese National Influenza Center (CNIC) and the United States Centers for Disease Control and Prevention (USCDC) initiated Cooperative Agreements to build capacity in influenza surveillance in China.From 2004 to 2014, CNIC and USCDC collaborated on the following activities: 1) developing human technical expertise in virology and epidemiology in China; 2) developing a comprehensive influenza surveillance system by enhancing influenza-like illness (ILI) reporting and virological characterization; 3) strengthening analysis, utilization and dissemination of surveillance data; and 4) improving early response to influenza viruses with pandemic potential.Since 2004, CNIC expanded its national influenza surveillance and response system which, as of 2014, included 408 laboratories and 554 sentinel hospitals. With support from USCDC, more than 2500 public health staff from China received virology and epidemiology training, enabling > 98% network laboratories to establish virus isolation and/or nucleic acid detection techniques. CNIC established viral drug resistance surveillance and platforms for gene sequencing, reverse genetics, serologic detection, and vaccine strains development. CNIC also built a bioinformatics platform to strengthen data analysis and utilization, publishing weekly on-line influenza surveillance reports in English and Chinese. The surveillance system collects 200,000-400,000 specimens and tests more than 20,000 influenza viruses annually, which provides valuable information for World Health Organization (WHO) influenza vaccine strain recommendations. In 2010, CNIC became the sixth WHO Collaborating Centre for Influenza. CNIC has strengthened virus and data sharing, and has provided training and reagents for other countries to improve global capacity for influenza control and prevention.The collaboration's successes were built upon shared mission and values, emphasis on long-term capacity development and sustainability, and leadership commitment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.